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Rapid Review
Last year saw reports on the effect of omalizumab (anti-IgE
therapy) in severe allergic asthma.1,2 The licensing of this
agent in the USA has had an impact on severe disease.
These results add to other studies3–5 (table) supporting an
add-on beneﬁt of omalizumab compared with placebo,
with reduction in inhaled-steroid dose and fewer ex-
acerbations requiring oral corticosteroids.
A major endpoint for most of the omalizumab studies
was reduction in inhaled-steroid dose. Meta-analysis sug-
gested a reduction of about 100 g a day over that achieved
in placebo-randomised patients.6 Exacerbation rates and
symptom scores were also reduced but without overall
changes in lung function in most studies.6 In controlled
trials of omalizumab in moderate-to-severe asthma,1,3,4
inhaled-steroid dose could also be reduced in many
patients on placebo and other proven add-on therapies
were often not used (eg, under half were taking long-
acting 2 agonists1). These results raise the issues of how
to select patients, how response is to be assessed, and
whether the cost of treatment (more than US$10 000 a
year) is justiﬁed. Other immunotherapies, such as anti-
bodies to tumour necrosis factor , might prove useful in
asthma,7 and as expensive and complex therapies become
available, it will be important to carefully identify which
patients will beneﬁt and target therapy appropriately.
Deﬁnition of severe asthma
Deﬁning asthma severity on the basis of persisting symp-
toms despite high-dose inhaled steroids is problematic,
and systematic evaluations of difﬁcult-to-manage asthma
give insight into the role of different factors in this pop-
ulation.8,9 A universal deﬁnition of severe asthma is difﬁ-
cult because of different patterns of disease. For example,
frequent severe exacerbations on the background of rel-
atively normal lung function (type 2 brittle asthma10)
would be deﬁned by most as severe but might not ﬁt a
deﬁnition based on a single assessment. There are work-
shop deﬁnitions of difﬁcult-to-treat asthma,11,12 similar to
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Context Asthma is readily diagnosed in most cases and usually responds to inhaled corticosteroids with or without long-
acting  agonists, theophyllines, or leukotriene-receptor antagonists, adjusted stepwise according to symptoms and lung
function. However, up to 40% of adult patients with asthma remain symptomatic, and up to 5% have difﬁcult-to-control
asthma despite multiple therapies. It is suggested that higher doses of inhaled steroids with long-acting 2 agonists
should be used for total control of symptoms; and anti-IgE therapy is newly licensed in the USA. However, difﬁcult-to-
control asthma is complex and multifactorial, and is often not due to severe or therapy-resistant asthma.
Starting point Last year saw encouraging reports on omalizumab (anti-IgE therapy) in severe allergic asthma, by Stephen
Holgate, Jon Ayres, and their respective colleagues (Clin Exp Allergy 2004; 34: 632–38; Allergy 2004; 59: 701–08).
Omalizumab reduced exacerbation rates, improved asthma symptoms and quality of life, and allowed lower doses of
inhaled steroid compared with placebo. In placebo-controlled studies with anti-IgE, many patients were able to
substantially reduce and even withdraw inhaled steroids in the placebo arm.
Where next Severe asthma is often deﬁned as persisting symptoms despite high-dose inhaled steroids. This deﬁnition is
likely to include patients with various reasons for their persisting symptoms, for whom additional treatment is not
always required. Before starting new therapy, it is important to systematically evaluate asthmatic patients to accurately
deﬁne their disease and to identify those whose symptoms are caused by other factors, and thus avoid unnecessary
medication. There might also be subgroups that have differing underlying inﬂammatory processes and who will
respond differently to individual treatments.
Study Mean inhaled steroid Patients (%) reducing Number (%) withdrawing Exacerbations during steroid Other major outcomes (compared with 
dose at study entry (g) inhaled-steroid dose by 50% inhaled steroids reduction (mean per patient) placebo)
Placebo Anti-IgE Placebo Anti-IgE Placebo Anti-IgE Placebo Anti-IgE
Holgate et al1 1362·5 1375·0 51 74* 15 21 0·34 0·19 Clinically signiﬁcant improvement in asthma 
(ﬂuticasone propionate) quality-of-life (39% vs 58%); improvements in 
symptom scores and rescue medication
Soler et al3 772·1 769·0 55 79 19 43 0·75 0·36† Improvements in symptom scores, lung function, 
(beclamethasone diproprionate) and rescue medication
Busse et al4 568 570 55 72† 19 40‡ 0·66 0·39‡ Improvements in symptom scores, lung function, 
(beclamethasone diproprionate) and rescue medication
*p=0·001, †p0·001, ‡p=0·003.
Table: Placebo-controlled trials in moderate-to-severe allergic asthma
Rapid Review
those used in two recent series.8,9 The American Thoracic
Society suggested major and minor diagnostic criteria for
refractory asthma.11 The patient should have mild-to-
moderate symptoms despite treatment requiring contin-
uous or near-continuous oral corticosteroids or high-dose
inhaled steroids (equivalent to at least 1000 g ﬂuticasone
propionate a day). Also, the patient should have two of:
requirement for additional long-acting 2 agonist, theo-
phylline, or leukotriene-receptor antagonist, symptoms re-
quiring daily or near daily use of short-acting 2 agonists,
persistent airﬂow obstruction (80% of predicted forced
expiratory volume in 1 s), one or more urgent-care visits a
year, three or more oral-steroid bursts a year, prompt
deterioration on reducing inhaled-steroid dose, or a near-
fatal past asthma event.11 This deﬁnition requires that
other conditions have been excluded, exacerbating factors
treated, and the patient is generally adherent.
Other diagnoses and exacerbating factors
Several conditions that cause respiratory symptoms might
co-exist in asthmatic patients, leading to an apparent
failure to respond to therapy. In both systematic eval-
uations,8,9 additional or alternative diagnoses were revealed
in just over a third of cases (ﬁgure). There are several other
additional or co-existent conditions that might make
asthma difﬁcult to control: smoking and chronic obstruct-
ive pulmonary disease, allergic bronchopulmonary asper-
gillosis, bronchiectasis, chronic infection (including chla-
mydia), rhinosinusitis, vocal-cord dysfunction, gastro-
oesophageal reﬂux, allergen or occupational exposure,
aspirin, systemic disease (eg, thyroid disease, vasculitis),
psychological factors, poor adherence, and socioeconomic
factors.8–11 Dysfunctional breathlessness seems prevalent
in all grades of asthma,8,9,13 and in a small series of patients
previously designated as having steroid-resistant asthma,
when properly evaluated, seven of 14 had evidence of
hyperventilation.14 Identiﬁcation and management of the
condition causing the symptoms, rather than more
asthma therapy, is a more appropriate strategy.
Although asthma might remain difﬁcult to control if
unidentiﬁed exacerbating factors persist, there is little
evidence that treating such factors has much effect on
asthma control. Inhaled allergens might be important in
driving asthmatic inﬂammation, although success with
allergen-avoidance strategies has yet to be convincingly
shown.15,16 Occupational exposure is amenable to inter-
vention, but was not a major problem in either cohort
(most patients were not working because of symptom
severity).8,9 Asthma may be exacerbated by ingestion of
certain drugs (eg, non-steroidal anti-inﬂammatory drugs
and  blockers).17,18 Gastro-oesophageal reﬂux often occurs
with asthma but evidence that treatment of reﬂux affects
asthma control is lacking;19 treatment was not associated
with better asthma outcome in the Belfast cohort.8
Rhinosinusitis is common in difﬁcult-to-treat asthma, but
again management did not relate to asthma outcome.8
Poor adherence and psychological factors
One of the commonest reasons for a poor response to
asthma therapy is not taking medication. The Brompton
study9 assessed adherence in those on oral prednisolone:
half had low or undetectable serum prednisolone and/or
normal cortisol, suggesting non-adherence. In the Belfast
cohort,20 11 of 44 patients taking theophylline and 14 of 25
taking prednisolone had unrecordable serum levels of
drug. Non-adherence with steroid therapy in this popul-
ation must be assessed when deﬁning “steroid-resistant”
or “(systemic) steroid-dependent” asthma. Non-adherence
also has major implications when reduction in steroid
therapy is an outcome, because rigorous assessment of
adherence is required. Assessing non-adherence with in-
haled therapy is difﬁcult, and issues that might lead to
poor adherence must be addressed at each clinic visit.
Reasons for poor adherence include lack of immediate
beneﬁt from anti-inﬂammatory therapy, side-effect fears,
resentment about the need for therapy, poor education,
economic restriction on access to health care, demo-
graphic factors such as sex and ethnicity, and secondary
gain.21 Adherence should be better with omalizumab,
because this drug is injected subcutaneously (fortnightly
or monthly; home therapy would raise issues of adher-
ence). But it seems difﬁcult to justify omalizumab for
asthma if other prescribed therapy is not being taken;
directly observed therapy or injected depot-steroids might
be more appropriate. Education and self-management
plans work, and are recommended in most guidelines.22 A
written management plan, careful follow-up, and addres-
sing non-adherence might be more cost effective than
injected bioengineered therapy in some patients.
It is hard to separate whether having difﬁcult-to-treat or
life-threatening asthma makes patients psychologically un-
stable, or whether psychiatric morbidity worsens asthma
control. Psychosocial morbidity is associated with asthma
death and near-fatal asthma in most but not all studies.23,24
In the Belfast cohort,8 32 of 65 (49%) sequential patients
had a psychiatric diagnosis, mainly depression, although
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Figure: Percentage of patients with alternative or co-existent diagnoses
causing symptoms in Belfast and Brompton studies8,9
Other=chronic bronchitis, IgA deﬁciency, cystic ﬁbrosis, obliterative bronchiolitis,
cardiomyopathy, pulmonary hypertension, hypereosinophilia, extrinsic allergic
alveolitis, and respiratory muscle in-coordination.
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identiﬁcation and appropriate management was not
associated with better asthma outcome. In the Brompton
cohort,9 33 of 88 (38%) patients had a psychiatric com-
ponent to their asthma. However, whether psychological
factors are causally linked with asthma severity or whether
management of identiﬁed psychiatric morbidity can affect
asthma outcome remains unclear.
Therapy-resistant asthma
Therapy-resistant asthma has been deﬁned as persisting
symptoms due to asthma despite high-dose inhaled
steroids (2000 g beclomethasone diproprionate or equiv-
alent) plus long-acting 2 agonist, with the requirement
for either maintenance systemic steroids or at least two
rescue courses of steroids over 12 months and despite
trials of add-ons such as a leukotriene-receptor antagonist
or theophylline.8 These are the patients for whom omali-
zumab might be appropriate.
Key to this deﬁnition is that persisting symptoms are
due to asthma, and other mechanisms and poor ad-
herence have been excluded. Addressing these issues with
systematic evaluation and management resulted in half
the patients with difﬁcult-to-treat asthma in the Belfast
study being stabilised with reduced treatment require-
ments.8 In the Brompton cohort, 34% of the patients with
difﬁcult-to-control asthma had alternative mechanisms for
persisting symptoms.9 Also, almost a third of the Bromp-
ton patients had ﬁxed airﬂow obstruction; whether this
form of asthma is amenable to novel interventions such as
anti-IgE therapy will be important to deﬁne.
Although further studies are required, there are differ-
ent characteristics of severe asthma that might require
alternative differing treatment strategies. Non-invasive
monitoring of inﬂammation can be used to guide therapy
and reduce exacerbation rates in asthma.25 Whether such
measures can identify subgroups, such as those with
persistent eosinophilic inﬂammation who might respond
to anti-interleukin-5 therapy (most patients do not26)
remains to be seen. Understanding the underlying mech-
anisms of refractory asthma is a future priority.
Conclusion
Omalizumab holds great promise for difﬁcult-to-control
asthma. However, before using expensive new therapies,
patients with difﬁcult-to-manage asthma should be sys-
tematically characterised so that new treatments are
appropriately targeted.
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